Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Intravenous indocyanine green dye is insufficient for robust immune cell labelling in the human retina.

Bell OH, Carreño E, Williams EL, Wu J, Copland DA, Bora M, Kobayter L, Fruttiger M, Sim DA, Lee RWJ, Dick AD, Chu CJ.

PLoS One. 2020 Feb 13;15(2):e0226311. doi: 10.1371/journal.pone.0226311. eCollection 2020.

2.

Single Eye mRNA-Seq Reveals Normalisation of the Retinal Microglial Transcriptome Following Acute Inflammation.

Bell OH, Copland DA, Ward A, Nicholson LB, Lange CAK, Chu CJ, Dick AD.

Front Immunol. 2020 Jan 9;10:3033. doi: 10.3389/fimmu.2019.03033. eCollection 2019.

3.

Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9.

Wu J, Bell OH, Copland DA, Young A, Pooley JR, Maswood R, Evans RS, Khaw PT, Ali RR, Dick AD, Chu CJ.

Mol Ther. 2020 Jan 10. pii: S1525-0016(20)30007-1. doi: 10.1016/j.ymthe.2019.12.012. [Epub ahead of print]

4.

Features of ectopic lymphoid-like structures in human uveitis.

Epps SJ, Coplin N, Luthert PJ, Dick AD, Coupland SE, Nicholson LB.

Exp Eye Res. 2020 Feb;191:107901. doi: 10.1016/j.exer.2019.107901. Epub 2019 Dec 23.

5.

The Relationship Between Ambient Atmospheric Fine Particulate Matter (PM2.5) and Glaucoma in a Large Community Cohort.

Chua SYL, Khawaja AP, Morgan J, Strouthidis N, Reisman C, Dick AD, Khaw PT, Patel PJ, Foster PJ; UK Biobank Eye and Vision Consortium.

Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4915-4923. doi: 10.1167/iovs.19-28346.

PMID:
31764948
6.

Modelling Macular Edema: The Effect of IL-6 and IL-6R Blockade on Human Blood-Retinal Barrier Integrity In Vitro.

Mesquida M, Drawnel F, Lait PJ, Copland DA, Stimpson ML, Llorenç V, Sainz de la Maza M, Adan A, Widmer G, Strassburger P, Fauser S, Dick AD, Lee RWJ, Molins B.

Transl Vis Sci Technol. 2019 Oct 28;8(5):32. doi: 10.1167/tvst.8.5.32. eCollection 2019 Sep.

7.

A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration.

Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, Ueffing M, Zarbin M, Farrer LA.

Nat Commun. 2019 Jul 26;10(1):3347. doi: 10.1038/s41467-019-11262-1. Review.

8.

Management of paediatric ocular inflammatory disease in the UK: national survey of practice.

Solebo AL, Rahi JS, Edelsten C, Ashworth JL, Dick AD; Paediatric Ocular Inflammation Group.

Eye (Lond). 2019 Jul 9. doi: 10.1038/s41433-019-0518-8. [Epub ahead of print] No abstract available.

PMID:
31289355
9.

Corrigendum to "Restoring retinal neurovascular health via substance P" [Exp. Cell Res. (2019)].

Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Schrader S, Liu L, Dick AD.

Exp Cell Res. 2019 Sep 15;382(2):111482. doi: 10.1016/j.yexcr.2019.06.027. Epub 2019 Jul 5. No abstract available.

10.

Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis: 5-Year Follow-up of the Bristol Participants of the SYCAMORE Trial.

Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RW, Dick AD, Ramanan AV.

Am J Ophthalmol. 2019 Nov;207:170-174. doi: 10.1016/j.ajo.2019.06.007. Epub 2019 Jun 13.

PMID:
31201796
11.

Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK.

Solebo AL, Rahi JS, Dick AD, Ramanan AV, Ashworth J, Edelsten C; Members of the POIG Uveitis Delphi Group.

Br J Ophthalmol. 2020 Jan;104(1):11-16. doi: 10.1136/bjophthalmol-2018-313789. Epub 2019 May 2.

PMID:
31048286
12.

Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.

Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, Williamson PR, Hardwick B, Hickey H, Rainford N, Hickey G, Kolamunnage-Dona R, Culeddu G, Plumpton C, Wood E, Compeyrot-Lacassagne S, Woo P, Edelsten C, Beresford MW.

Health Technol Assess. 2019 Apr;23(15):1-140. doi: 10.3310/hta23150.

13.

Restoring retinal neurovascular health via substance P.

Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Schrader S, Liu L, Dick AD.

Exp Cell Res. 2019 Jul 15;380(2):115-123. doi: 10.1016/j.yexcr.2019.04.008. Epub 2019 Apr 14. Erratum in: Exp Cell Res. 2019 Jul 5;:.

14.

Müller Cells Stabilize Microvasculature through Hypoxic Preconditioning.

Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Scott LM, Dick AD, Schrader S, Liu L.

Cell Physiol Biochem. 2019;52(4):668-680. doi: 10.33594/000000047.

15.

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial).

Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H, Lee R, McKay A, Beresford MW; APTITUDE Trial Management Group.

BMC Rheumatol. 2018 Feb 27;2:4. doi: 10.1186/s41927-018-0010-2. eCollection 2018.

16.

Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.

Sharma SM, Damato E, Hinchcliffe AE, Andrews CD, Myint K, Lee R, Dick AD.

Br J Ophthalmol. 2019 Mar 12. pii: bjophthalmol-2018-312767. doi: 10.1136/bjophthalmol-2018-312767. [Epub ahead of print]

17.

Reply.

Hughes DA, Culeddu G, Plumpton C, Wood E, Dick AD, Beresford MW, Ramanan AV.

Ophthalmology. 2019 Mar;126(3):e24-e25. doi: 10.1016/j.ophtha.2018.12.005. No abstract available.

PMID:
30803529
18.

The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation.

Hu X, Schewitz-Bowers LP, Lait PJP, Copland DA, Stimpson ML, Li JJ, Liu Y, Dick AD, Lee RWJ, Wei L.

Curr Mol Med. 2018;18(9):594-601. doi: 10.2174/1566524019666190126112238.

PMID:
30683020
19.

Reduced Macular Vessel Density and Capillary Perfusion in Glaucoma Detected Using OCT Angiography.

Wu J, Sebastian RT, Chu CJ, McGregor F, Dick AD, Liu L.

Curr Eye Res. 2019 May;44(5):533-540. doi: 10.1080/02713683.2018.1563195. Epub 2019 Jan 2.

PMID:
30577706
20.

Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.

Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD, Chakravarthy U.

Ophthalmol Retina. 2018 Feb;2(2):118-127. doi: 10.1016/j.oret.2017.05.015.

21.

Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis.

Hughes DA, Culeddu G, Plumpton CO, Wood E, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot Lacassagne S, Hardwick B, Hickey H, Woo P, Beresford MW, Ramanan AV.

Ophthalmology. 2019 Mar;126(3):415-424. doi: 10.1016/j.ophtha.2018.09.043. Epub 2018 Oct 16.

PMID:
30336181
22.

Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation.

Carreno E, Clench T, Steeples LR, Salvatore S, Lee RWJ, Dick AD, Pawade J.

Acta Ophthalmol. 2019 Feb;97(1):e138-e139. doi: 10.1111/aos.13808. Epub 2018 Aug 16. No abstract available.

23.

Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy.

Cann M, Ramanan AV, Crawford A, Dick AD, Clarke SLN, Rashed F, Guly CM.

Pediatr Rheumatol Online J. 2018 Aug 6;16(1):51. doi: 10.1186/s12969-018-0266-5.

24.

Reply.

Dick AD, Rosenbaum JT.

Ophthalmology. 2018 Aug;125(8):e54. doi: 10.1016/j.ophtha.2018.03.006. No abstract available.

PMID:
30032799
25.

A Perspective of AMD Through the Eyes of Immunology.

Copland DA, Theodoropoulou S, Liu J, Dick AD.

Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD83-AMD92. doi: 10.1167/iovs.18-23893. Review.

PMID:
30025105
26.

Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.

Goto H, Zako M, Namba K, Hashida N, Kaburaki T, Miyazaki M, Sonoda KH, Abe T, Mizuki N, Kamoi K, Brézin AP, Dick AD, Jaffe GJ, Nguyen QD, Inomata N, Kwatra NV, Camez A, Song AP, Kron M, Tari S, Ohno S.

Ocul Immunol Inflamm. 2019;27(1):40-50. doi: 10.1080/09273948.2018.1491605. Epub 2018 Jul 17.

27.

The Eyes Have it: A Rheumatologist's View of Uveitis.

Rosenbaum JT, Dick AD.

Arthritis Rheumatol. 2018 Oct;70(10):1533-1543. doi: 10.1002/art.40568. Epub 2018 Aug 23. Review.

28.

C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration.

Molins B, Romero-Vázquez S, Fuentes-Prior P, Adan A, Dick AD.

Front Immunol. 2018 Apr 19;9:808. doi: 10.3389/fimmu.2018.00808. eCollection 2018. Review.

29.

Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.

Leal I, Rodrigues FB, Sousa DC, Romão VC, Duarte GS, Carreño E, Dick AD, Marques-Neves C, Costa J, Fonseca JE.

Acta Ophthalmol. 2018 Sep;96(6):e665-e675. doi: 10.1111/aos.13699. Epub 2018 Mar 25. Review.

30.

Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics.

Armitage WJ, Winton HL, Jones MNA, Crewe JM, Rogers CA, Tole DM, Dick AD.

Br J Ophthalmol. 2019 Jan;103(1):132-136. doi: 10.1136/bjophthalmol-2017-311342. Epub 2018 Mar 22.

PMID:
29567793
31.

Re-programming immunosurveillance in persistent non-infectious ocular inflammation.

Epps SJ, Boldison J, Stimpson ML, Khera TK, Lait PJP, Copland DA, Dick AD, Nicholson LB.

Prog Retin Eye Res. 2018 Jul;65:93-106. doi: 10.1016/j.preteyeres.2018.03.001. Epub 2018 Mar 9. Review.

32.

Autoimmunity, Autoinflammation, and Infection in Uveitis.

Forrester JV, Kuffova L, Dick AD.

Am J Ophthalmol. 2018 May;189:77-85. doi: 10.1016/j.ajo.2018.02.019. Epub 2018 Mar 2. Review.

33.

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.

Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD.

Ophthalmology. 2018 Jul;125(7):1075-1087. doi: 10.1016/j.ophtha.2017.12.039. Epub 2018 Feb 9.

34.

Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.

Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, Cook A, Gattamaneni R, Jain R, Olver J, Hurel SJ, Bremner F, Drummond SR, Kemp E, Ritchie DM, Rumsey N, Morris D, Lane C, Palaniappan N, Li C, Pell J, Hills R, Ezra DG, Potts MJ, Jackson S, Rose GE, Plowman N, Bunce C, Uddin JM, Lee RWJ, Dayan CM.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):299-309. doi: 10.1016/S2213-8587(18)30021-4. Epub 2018 Jan 31.

PMID:
29396245
35.

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.

Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, Davis JL, Ramanan AV, Sonoda KH, Carreño E, Nascimento H, Salah S, Salek S, Siak J, Steeples L; Fundamentals of Care for Uveitis International Consensus Group.

Ophthalmology. 2018 May;125(5):757-773. doi: 10.1016/j.ophtha.2017.11.017. Epub 2018 Jan 6.

36.

Augmenting Endogenous Levels of Retinal Annexin A1 Suppresses Uveitis in Mice.

Gardner PJ, Yazid S, Ribeiro J, Ali RR, Dick AD.

Transl Vis Sci Technol. 2017 Oct 5;6(5):10. doi: 10.1167/tvst.6.5.10. eCollection 2017 Sep.

37.

Application of OCT-angiography to characterise the evolution of chorioretinal lesions in acute posterior multifocal placoid pigment epitheliopathy.

Burke TR, Chu CJ, Salvatore S, Bailey C, Dick AD, Lee RWJ, Ross AH, Carreño E; Medscape.

Eye (Lond). 2017 Oct;31(10):1399-1408. doi: 10.1038/eye.2017.180. Epub 2017 Oct 6.

38.

Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.

Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Dick AD, Espada G, Fernandez-Martin J, Guly CM, Hachulla E, Harjacek M, Khubchandani R, Mackensen F, Merino R, Modesto C, Naranjo A, Oliveira-Knupp S, Özen S, Pajot C, Ramanan AV, Russo R, Susic G, Thatayatikom A, Thomée C, Vastert S, Bertin J, Arostegui JI, Rose CD, Wouters CH.

Am J Ophthalmol. 2018 Mar;187:158-166. doi: 10.1016/j.ajo.2017.08.017. Epub 2017 Sep 6.

PMID:
28887115
39.

Adalimumab for Uveitis in Juvenile Idiopathic Arthritis.

Ramanan AV, Dick AD, Beresford MW.

N Engl J Med. 2017 Aug 24;377(8):789-790. doi: 10.1056/NEJMc1708646. No abstract available.

PMID:
28834482
40.

Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis.

Sen ES, Morgan MJ, MacLeod R, Strike H, Hinchcliffe A, Dick AD, Muthusamy B, Ramanan AV.

Pediatr Rheumatol Online J. 2017 Aug 4;15(1):58. doi: 10.1186/s12969-017-0189-6.

41.

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.

Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW; SYCAMORE Study Group.

N Engl J Med. 2017 Apr 27;376(17):1637-1646. doi: 10.1056/NEJMoa1614160.

42.

Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.

Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.

JAMA Ophthalmol. 2017 Jun 1;135(6):511-518. doi: 10.1001/jamaophthalmol.2017.0603.

43.

Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis.

Makragiannis G, Vahdani K, Carreño E, Lee RWJ, Dick AD, Ross AH.

Int Ophthalmol. 2018 Apr;38(2):781-785. doi: 10.1007/s10792-017-0502-x. Epub 2017 Mar 30.

PMID:
28361379
44.

Hypoxia inducible factors are dispensable for myeloid cell migration into the inflamed mouse eye.

Gardner PJ, Liyanage SE, Cristante E, Sampson RD, Dick AD, Ali RR, Bainbridge JW.

Sci Rep. 2017 Jan 23;7:40830. doi: 10.1038/srep40830.

45.

Cataract surgery in uveitis: a multicentre database study.

Chu CJ, Dick AD, Johnston RL, Yang YC, Denniston AK; UK Pseudophakic Macular Edema Study Group.

Br J Ophthalmol. 2017 Aug;101(8):1132-1137. doi: 10.1136/bjophthalmol-2016-309047. Epub 2017 Jan 2.

PMID:
28043984
46.

An anti-TNF-α antibody mimetic to treat ocular inflammation.

Khalili H, Lee RW, Khaw PT, Brocchini S, Dick AD, Copland DA.

Sci Rep. 2016 Nov 22;6:36905. doi: 10.1038/srep36905.

47.

Soluble CD200 Correlates With Interleukin-6 Levels in Sera of COPD Patients: Potential Implication of the CD200/CD200R Axis in the Disease Course.

Sakthivel P, Breithaupt A, Gereke M, Copland DA, Schulz C, Gruber AD, Dick AD, Schreiber J, Bruder D.

Lung. 2017 Feb;195(1):59-68. doi: 10.1007/s00408-016-9962-4. Epub 2016 Nov 18.

PMID:
27864635
48.

Optical Coherence Tomography Angiography Findings in Dengue-Related Maculopathy: A Case Report.

Tavassoli S, Carreño E, Teoh SC, Theodoropoulou S, Bailey C, Lee RW, Dick AD.

Ophthalmic Surg Lasers Imaging Retina. 2016 Nov 1;47(11):1057-1060. doi: 10.3928/23258160-20161031-12.

PMID:
27842202
49.

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.

Willis MD, Pickersgill TP, Robertson NP, Lee RWJ, Dick AD, Carreño E.

Int Ophthalmol. 2017 Oct;37(5):1229-1233. doi: 10.1007/s10792-016-0370-9. Epub 2016 Oct 11.

PMID:
27730316
50.

Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye.

Theodoropoulou S, Copland DA, Liu J, Wu J, Gardner PJ, Ozaki E, Doyle SL, Campbell M, Dick AD.

J Pathol. 2017 Jan;241(1):45-56. doi: 10.1002/path.4816. Epub 2016 Nov 16.

Supplemental Content

Support Center